HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis.

Abstract
PTH administration increases bone mass in rodents and in humans. PTH-related protein (PTHrP) binds to and signals via the skeletal PTH receptor. Administration of PTHrP on a once daily basis increases bone mineral content in rats. In humans, PTHrP-(1-36) is equipotent to PTH-(1-34) and is active when administered s.c. These findings suggest that PTHrP might have therapeutic benefit in the treatment of osteoporosis. In this study, 13 postmenopausal estrogen-deficient women received a single daily s.c. dose of PTHrP-(1-36) for a 14-day period to determine whether PTHrP-(1-36) 1) could be given in doses that do not alter systemic mineral homeostasis, but increase markers of bone turnover; and 2) is tolerated without adverse effects. Daily s.c. PTHrP-(1-36) administration caused no significant changes in serum calcium or phosphorus concentrations, fractional calcium excretion, the tubular maximum for phosphorus, fractional calcium excretion, or plasma 1,25-dihydroxyvitamin D concentrations. Nephrogenous cAMP and endogenous PTH-(1-84) declined. Importantly, markers of bone formation trended upward, as reported in subjects treated with PTH. In marked contrast to findings in PTH-treated subjects, in PTHrP-treated subjects, markers of bone resorption declined in a highly significant fashion. These observations indicate that PTHrP-(1-36) treatment uncouples bone formation from resorption, in favor of formation. This uncoupling, if it were to continue over the longer term, would predict that PTHrP-(1-36) might be a potent anabolic therapeutic agent for osteoporosis.
AuthorsH Plotkin, C Gundberg, M Mitnick, A F Stewart
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 83 Issue 8 Pg. 2786-91 (Aug 1998) ISSN: 0021-972X [Print] United States
PMID9709948 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Parathyroid Hormone
  • Parathyroid Hormone-Related Protein
  • Peptide Fragments
  • Proteins
  • parathyroid hormone-related peptide (1-36)
  • Phosphorus
  • Cyclic AMP
  • Calcitriol
  • Calcium
Topics
  • Bone Development (physiology)
  • Bone Remodeling
  • Bone Resorption
  • Calcitriol (blood)
  • Calcium (blood, urine)
  • Cyclic AMP (metabolism)
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Middle Aged
  • Osteoporosis (drug therapy)
  • Parathyroid Hormone (blood)
  • Parathyroid Hormone-Related Protein
  • Peptide Fragments (administration & dosage, pharmacology, therapeutic use)
  • Phosphorus (blood)
  • Postmenopause
  • Proteins (administration & dosage, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: